Supports

Evolocumab Overview

Introduction of Evolocumab

Evolocumab is a fully human monoclonal antibody (IgG2λ type) designed for the treatment of hyperlipidemia by Amgen. It targets the proprotein convertase subtilisin/kexin type 9 (PCSK9). With the trade name Repatha, evolocumab has been successively approved for marketing in USA, European Union, Canada, Australia, and Japan.

Mechanism of Action of Evolocumab

Evolocumab recognizes and attaches to the enzyme PCSK9. This enzyme attaches to cholesterol receptors on the surface of liver cells and causes these receptors to be absorbed and broken down inside the cells. By attaching and blocking PCSK9, Repatha prevents the receptors from being broken down and therefore increases their numbers on the cell surface, where they can attach to low-density lipoprotein-cholesterol (LDL-C) and remove it from the bloodstream. This helps to reduce the amount of cholesterol in the blood. Repatha also helps to reduce other fatty substances from blood in patients with mixed dyslipidemia.

Fig.1 Mechanism of action of evolocumab

Clinical Projects of Evolocumab*

NCT ID

Status

Conditions

Lead Sponsor

Update Time

NCT03480568	Not yet recruiting	Hemodialysis, Peritoneal Dialysis, Hypercholesterolemia, Atherosclerotic Disease	Baylor Research Institute	March 29, 2018
NCT03533959	Recruiting	Coronary Artery Disease Progression	Kobe University	May 23, 2018
NCT02938949	Recruiting	Myocardial Infarction, Hypercholesterolemia	Virginia Commonwealth University	October 19, 2016
NCT03529253	Recruiting	Coronary Artery Disease, Angina Pectoris	Kobe University	May 18, 2018
NCT03014830	Active, not recruiting	Atherosclerosis, Coronary Heart Disease	Washington University School of Medicine	January 9, 2017
NCT03379558	Recruiting	Hypercholesterolemia	Sanofi	December 20, 2017
NCT03542110	Not yet recruiting	Saphenous Vein Graft Atherosclerosis	Minneapolis Heart Institute Foundation	May 31, 2018
NCT03344692	Not yet recruiting	Type2 Diabetes	Nantes University Hospital	November 17, 2017
NCT02959047	Recruiting	Peripheral Arterial Disease	University of Virginia	November 8, 2016
NCT03004001	Recruiting	Nephrotic Syndrome	Gloria Vega	December 28, 2016
NCT03067844	Recruiting	Coronary Vessel, Coronary Circulation, Myocardial Atheroma	University Hospital Inselspital, Berne	March 1, 2017
NCT02992301	Recruiting	Atherosclerosis, Hyperlipidemia	Westside Medical Associates of Los Angeles	December 14, 2016
NCT03510715	Not yet recruiting	Hypercholesterolemia	Sanofi	April 27, 2018
NCT03510884	Recruiting	Hypercholesterolemia	Sanofi	April 27, 2018
NCT02715726	Active, not recruiting	Hypercholesterolemia	Sanofi	March 22, 2016
NCT02890992	Recruiting	Hypercholesterolemia	Sanofi	September 7, 2016
NCT02984982	Active, not recruiting	Hypercholesterolemia, Acute Coronary Syndrome	Sanofi	December 7, 2016
NCT02476006	Active, not recruiting	Hypercholesterolemia	Sanofi	June 19, 2015
NCT02957682	Active, not recruiting	Hypercholesterolemia	Regeneron Pharmaceuticals	November 8, 2016
NCT03273972	Recruiting	Atherosclerosis, Cardiovascular Diseases	Cambridge University Hospitals NHS Foundation Trust	September 6, 2017
NCT03355027	Recruiting	Atherosclerosis, Cardiovascular Diseases	Cambridge University Hospitals NHS Foundation Trust	November 28, 2017
NCT03156621	Recruiting	Homozygous Familial Hypercholesterolemia	Regeneron Pharmaceuticals	May 17, 2017
NCT03415178	Active, not recruiting	Hypercholesterolemia	Sanofi	January 30, 2018
NCT03507374	Not yet recruiting	Stroke, Intracranial Atherosclerosis, Intraplaque Hemorrhage	University of Utah	April 25, 2018

Approved Drugs of Evolocumab**

INN (trade name)	Therapeutic area	Dose	Strength	Route	Company	Marketing start	Market
Repatha	Dyslipidemias, Hypercholesterolemia	Injection, Solution	140 mg/mL	Subcutaneous	Amgen Europe B.V.	July 17, 2015
Repatha	Heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease	Injection, Solution	140 mg/mL	Subcutaneous	Amgen Inc.	August 27, 2015
Repatha	Cardiovascular Events, Primary Hyperlipidemia, Homozygous Familial Hypercholesterolemia, Geriatrics, Pediatrics	Injection, Solution	140 mg/mL	Subcutaneous	Amgen Canada Inc.	September 28, 2015
Repatha	Heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease	Injection, Solution	120/140 mg/mL	Subcutaneous	Amgen Australia Pty Ltd.	December 9, 2015
Repatha	Hypercholesterolemia	Injection, Solution	140 mg/mL	Subcutaneous	Amgen Astellas BioPharma K.K.	January 22, 2016

What We Provide

Therapeutic Antibody

Evolocumab

We provide high-quality Evolocumab for use in WB, FC, IP, ELISA, Neut, FuncS, IF and most other immunological methods. For lab research use only, not for diagnostic, therapeutic or any in vivo human use.

Resources
* The table was excerpted from the following website
https://clinicaltrials.gov/ct2/results?cond=&term=Evolocumab

** Information presented in the table were collected from the following websites:
http://www.pmda.go.jp/PmdaSearch/iyakuDetail/GeneralList/2189401G1
https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=93132
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125522
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003766/human_med_001890.jsp
http://search.tga.gov.au/s/search.html?collection=tga-artg&profile=record&meta_i=231151

For research use only. Not intended for any clinical use.